Akebia Therapeutics entered a term loan facility with Symbiotic Capital on November 12, 2026. It funded a $60.0 million tranche, repaid its $55.0 million BlackRock loan in full, and may request up to $80.0 million more, subject to lender discretion.
AKBA · Akebia Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.42
- Open
- $0.40
- Day range
- $0.40–0.43
- 52-week closing range
- $0.40–1.70
- Average volume, 30 days
- 8.4M
- Short interest
- 27.2M · 9.8% of shares · 3.0 days
- Short volume, last session
- 56%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Akebia reported $36.9 million in Q3 revenue, a $14.4 million net loss and $159.3 million cash, while Vafcio reached about 11,500 patients and VOICE showed 10% fewer hospitalizations than ESAs.
Akebia Therapeutics, Inc. reported product revenue of $133.6 million and a net loss of $32.3 million for the nine months ended September 30, 2026. Lower Auryxia revenue from reduced pricing and sales volume amid generic competition drove the decline.
Akebia Therapeutics reported $36.9 million in Q3 2026 revenue and a $14.4 million net loss, while Vafseo net product revenue reached $14.8 million with approximately 11,500 active patients and $159.3 million in cash.
Nasdaq notified Akebia that its stock closed below $1.00 for the last 30 consecutive business days, with no immediate effect on listing. Compliance requires closing at or above $1.00 for 10 consecutive business days by April 19, 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Akebia reported strong sequential Vafseo revenue and patient growth, and announced a positive interim VOICE trial result for Vafseo versus ESAs on mortality/hospitalization, while guiding 2027 Vafseo revenue to decline on planned price cuts after loss of tadapa exclusivity; Auryxia revenue continued to fall, driving a quarterly net loss.
- + Vafseo Q2 net product revenue grew 34% sequentially to $21.3 million, with over 10,500 patients on therapy (a 41% sequential increase) and ~1,200 prescribers.
- + VOICE interim analysis met stopping criteria, showing Vafseo statistically superior to ESAs on the composite of all-cause mortality and hospitalization (win odds 1.16; p=0.0016).
- + Phase 2 basket trial of ebribafusp in IgA nephropathy, lupus nephritis, and C3 glomerulopathy initiated, with initial data expected in 2027.
- + Vafseo IP portfolio strengthened with a new Orange Book-listed patent and a potential 5-year term extension, with portfolio expirations out to 2036.
- − Q2 swung to a net loss of $8.9 million from net income of $0.2 million a year ago, driven by lower revenue and higher expenses including a $1.9 million restructuring charge.
- − Management expects 2027 Vafseo revenue to decline versus 2026 due to a planned price reduction after expected end of tadapa on December 31, 2026.
- − Auryxia revenue fell to $25.5 million from $47.2 million year-over-year and is expected to continue declining in 2026 due to generic competition and pricing pressure.
- − R&D expense rose to $14.1 million from $11.0 million year-over-year on higher clinical activity and headcount costs.
- − Total revenue declined to $49.1 million from $62.5 million year-over-year due to lower Auryxia revenue.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients on Vafseo | 11,500 | end of Q3 2026 | — |
| Total number of prescribers | 1,300 | Q3 2026 | — |
| patients on Vafseo therapy | 10,500 | Q2 2026 | — |
| prescribers | 1,200 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKBA
this stock
Akebia Therapeutics, Inc.
|
$117.26M | -73.8% | +47.5% | — | 9.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.89B | +5.3% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 21
Akebia Therapeutics entered a term loan facility with Symbiotic Capital on November 12, 2026. It funded a $60.0 million tranche, repaid its $55.0 million BlackRock loan in full, and may request up to $80.0 million more, subject to lender discretion.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKBA | -15.2% | -24.9% | -58.6% | -40.2% | -73.8% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -9.8% | -18.6% | -53.0% | -35.0% | -78.8% |